Stage III Cutaneous Melanoma AJCC v7 Terminated Phase 1 Trials for Nivolumab (DB09035)
| Indication | Status | Phase |
|---|---|---|
| DBCOND0091046 (Stage III Cutaneous Melanoma AJCC v7) | Terminated | 1 |
| clinicaltrials.gov Identifier | Title | Purpose | Drugs |
|---|---|---|---|
| NCT01940809 | Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery | Treatment | |
| NCT03425461 | Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma | Treatment |